At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effectiveness and Safety of Once Weekly Insulin Icodec Used With DoseGuide Versus Once Daily Basal Insulin Analogues in an Insulin naïve Type 2 Diabetes Population in a Clinical Practice Setting
In Brief
A Phase 3 clinical trial evaluating Insulin icodec, Insulin Glargine 100U/mL, and 2 other interventions for Diabetes Mellitus, Type 2. Completed, enrolled 1,085 participants across 311 sites in 10 countries.
Signals
Detailed Summary
This study compares insulin icodec to different daily insulins in people with type 2 diabetes. The study will look at how well insulin icodec taken once weekly controls blood sugar compared to the insulins taken once daily. Participants will either get insulin icodec, that participants will have to inject once a week on the same day of the week, or a marketed insulin, that participants will have to inject once a day. Which treatment participants get is decided at random. The insulin is injected with a needle in a skin fold in the thigh, upper arm or stomach. Participants will measure their blood sugar every day. Participants will get a study phone to record safety data in the electronic diary (eDiary). If participants get a daily insulin they will record their insulin doses in the eDiary. If Participants get weekly insulin icodec, participants study phone will also have the DoseGuide App. The DoseGuide App gives dose recommendations based on their blood sugar and previous doses. Participants will record their insulin doses in the DoseGuide App. The study will last for about 1 year and 2 months. Participants will have 8 planned clinic visits with the study doctor. More visits will be planned to meet individual needs. At 6 clinic visits participants will have blood samples taken. Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Study Details
Timeline
Arms & Interventions
Participants randomised to insulin icodec will use insulin icodec with the DoseGuide App to guide their titration.
Participants randomised to basal insulin analogue injections once daily
Interventions
Participants will receive subcutaneous (s.c.) injections of insulin icodec once weekly for 52 weeks.
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.
Participants will receive subcutaneous (s.c.) injections of insulin analogues once daily for 52 weeks.